View Older Stories

Mar 30, 2026 08:32AM Ultragenyx receives FDA clearance for GNE myopathy drug trial

Mar 24, 2026 02:32AM Goldman Sachs Downgrades Ultragenyx Pharma (RARE) to Neutral

Mar 12, 2026 11:55AM BofA Securities Reiterates Buy Rating on Ultragenyx Pharma (RARE): "current valuation undervalues the pipeline opportunity"

Mar 12, 2026 11:55AM BofA Securities Reiterates Buy Rating on Ultragenyx Pharma (RARE): "current valuation undervalues the pipeline opportunity"

Mar 12, 2026 10:39AM Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE): "encouraged by this clinical win"

Feb 18, 2026 06:44AM Ultragenyx Pharma (RARE) PT Lowered to $79 at Canaccord Genuity

Feb 12, 2026 04:30PM Ultragenyx Pharma (RARE) Misses Q4 EPS by 14c, provides guidance

Feb 3, 2026 06:44AM H.C. Wainwright Reiterates Buy Rating on Ultragenyx Pharma (RARE)

Jan 30, 2026 08:31AM Ultragenyx resubmits gene therapy application for rare brain disease

Jan 12, 2026 07:31AM Ultragenyx reports preliminary 2025 revenue of $672-674 million

Jan 6, 2026 06:42AM Ultragenyx Pharma (RARE) PT Lowered to $60 at H.C. Wainwright

Jan 5, 2026 07:35AM Ultragenyx Pharma (RARE) PT Lowered to $52 at Guggenheim

Jan 2, 2026 05:25AM Ultragenyx Pharma (RARE) PT Lowered to $58 at BofA Securities

Dec 31, 2025 09:23AM Leerink on Ultragenyx Pharma (RARE): 'DTX401 Rolling BLA Submitted, Setting Up Launch for Underappreciated Program'

Dec 30, 2025 04:06PM Ultragenyx completes gene therapy application for rare metabolic disease

Dec 30, 2025 04:58AM Ultragenyx Pharma (RARE) PT Lowered to $45 at Wells Fargo

Dec 30, 2025 04:55AM Ultragenyx Pharma (RARE) PT Lowered to $63 at Jefferies

Dec 30, 2025 04:54AM Jefferies Downgrades Mereo BipPharma Group (MREO) to Hold

Dec 30, 2025 02:03AM Ultragenyx Pharma (RARE) PT Lowered to $71 at Goldman Sachs

Dec 29, 2025 03:27PM Ultragenyx Pharma (RARE) PT Lowered to $70 at Leerink Partners

Dec 29, 2025 03:27PM Mereo BipPharma Group (MREO) PT Lowered to $2 at Leerink Partners

Dec 29, 2025 01:50PM TD Cowen Reiterates Buy Rating on Ultragenyx Pharma (RARE)

Dec 29, 2025 01:11PM LifeSci Capital Downgrades Mereo BipPharma Group (MREO) to Market Perform

Dec 29, 2025 12:48PM Ultragenyx Pharma (RARE) PT Lowered to $47 at Baird

Dec 29, 2025 12:12PM Ultragenyx Pharma (RARE) PT Lowered to $50 (from $103) at Citi

Dec 29, 2025 12:04PM William Blair Reiterates Outperform Rating on Ultragenyx Pharma (RARE)

Dec 29, 2025 12:04PM Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE)

Dec 29, 2025 12:03PM Morgan Stanley Reiterates Overweight Rating on Ultragenyx Pharma (RARE)

Dec 29, 2025 12:03PM Truist Securities Reiterates Buy Rating on Ultragenyx Pharma (RARE)

Dec 29, 2025 08:25AM Ultragenyx Pharma (RARE) halted, news pending

Nov 21, 2025 07:13AM Cantor Fitzgerald Reiterates Overweight Rating on Ultragenyx Pharma (RARE)

Nov 5, 2025 09:34AM Citi Opens 90-Day Upside Catalyst Watch on Ultragenyx Pharma (RARE)

Nov 5, 2025 04:51AM Ultragenyx Pharma (RARE) PT Lowered to $72 at RBC Capital

Nov 4, 2025 04:19PM Ultragenyx Pharma (RARE) Misses Q3 EPS by 58c, provides guidance

Oct 17, 2025 05:56AM Ultragenyx Pharma (RARE) January 50 calls active

Sep 22, 2025 07:15AM Cantor Fitzgerald Reiterates Overweight Rating on Ultragenyx Pharma (RARE)

Sep 9, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Ultragenyx Pharma (RARE)

Aug 18, 2025 08:06AM Ultragenyx begins rolling FDA submission for GSDIa gene therapy

Jul 28, 2025 06:58AM H.C. Wainwright Assumes Ultragenyx Pharma (RARE) at Buy

Jul 14, 2025 08:01AM Health Canada approves Evkeeza for infants as young as 6 months with HoFH

Jul 14, 2025 05:08AM Ultragenyx Pharma (RARE) December options active

Jul 11, 2025 05:05PM Ultragenyx stock falls after FDA issues complete response letter for gene therapy

Jul 11, 2025 04:30PM Ultragenyx receives FDA rejection for gene therapy to treat rare disease

Jul 10, 2025 10:52AM TD Cowen: 'Ultragenyx Pharma (RARE) a Buying Oppy Ahead Of Dec '25 Readout'

Jul 10, 2025 07:49AM BTIG Reiterates Buy Rating on Mereo BipPharma Group (MREO)

Jul 10, 2025 07:43AM Morgan Stanley Reiterates Overweight Rating on Ultragenyx Pharma (RARE)

Jul 10, 2025 06:44AM Canaccord Genuity Reiterates Buy Rating on Ultragenyx Pharma (RARE)

Jul 10, 2025 06:42AM Ultragenyx Pharma (RARE) PT Lowered to $65 at Wells Fargo

Jul 10, 2025 06:20AM BofA Securities on Ultragenyx Pharma (RARE): 'top 2025 pick'

Jul 10, 2025 06:01AM Goldman Sachs Reiterates Buy Rating on Ultragenyx Pharma (RARE)

View Older Stories